The last decade has brought about major advances in systemic therapy for patients with advanced clear cell renal cell carcinoma.The introduction of angiogenesis targeting agents,immune checkpoint inhibitors,and combin...The last decade has brought about major advances in systemic therapy for patients with advanced clear cell renal cell carcinoma.The introduction of angiogenesis targeting agents,immune checkpoint inhibitors,and combinations thereof has resulted in a multitude of therapeutic standards for patients with newly diagnosed advanced disease.With the rapid adoption and increasing number of available options for patients,selection amongst treatment regimens has become complex.Further,a new balance is also being sought to optimize treatment outcomes and limit treatment-related toxicities.With a rising bar against which novel therapeutics are being measured,the field looks toward an evolved understanding of tumor biology to help pave new ways forward for individualized therapy.Here,we review pivotal studies that led to regulatory approvals and ongoing clinical trials conducted in patients with systemically untreated clear cell renal cell carcinoma and provide perspective on how newly emerging data can be integrated into this rapidly changing landscape.展开更多
文摘The last decade has brought about major advances in systemic therapy for patients with advanced clear cell renal cell carcinoma.The introduction of angiogenesis targeting agents,immune checkpoint inhibitors,and combinations thereof has resulted in a multitude of therapeutic standards for patients with newly diagnosed advanced disease.With the rapid adoption and increasing number of available options for patients,selection amongst treatment regimens has become complex.Further,a new balance is also being sought to optimize treatment outcomes and limit treatment-related toxicities.With a rising bar against which novel therapeutics are being measured,the field looks toward an evolved understanding of tumor biology to help pave new ways forward for individualized therapy.Here,we review pivotal studies that led to regulatory approvals and ongoing clinical trials conducted in patients with systemically untreated clear cell renal cell carcinoma and provide perspective on how newly emerging data can be integrated into this rapidly changing landscape.
